1. Create or login to your account using the options above
2. Click on "Submit Abstract(s)" option
3. Follow the steps and fill in all the requested information
4. Tick all the requiered mandatory fields to be able to submit an abstract
5. Click to "Submit abstract" or save it as draft – do not forget to submit it prior the deadline October 31, 2025
   Note: You can login to update your abstract until the deadline (October 31, 2025)

• Abstracts must be submitted via the online form only, abstracts submitted by email will not be accepted.
• Abstracts must be submitted in English, using UK English spelling.
• The presenting author of an accepted abstract must register and attend the congress.
• The number of submissions is limited to 3 per presenting author.
• The number of authors is limited to 20 per abstract.
• Provide a short specific title indicating the scientific content of the abstract. The background and goals of the study should appear clearly to the reader. The methods need to outline patient group, methods applied, statistical considerations, if applicable. Results must contain data (except for Late Breaking abstracts [LBA]- see below), and the conclusion should be clearly expressed. The following structure will be required:
  • Introduction/Background*
  • Methodology
  • Results*
  • Conclusion*
  • Disclosures* (online recording via the submission form)
    *mandatory fields
• The title may not exceed 30 words. PLEASE DO NOT USE CAPITAL LETTERS. The abstract text may not be longer than 300 words (excluding title, authors and disclosures).
• All abbreviations must be defined the first time they appear in the text (but do not define in the title).
• Tables charts and other graphics (for all in total maximum 1) are permitted and must be in high resolution JPG format.
• Authors should indicate their presentation type preference:
• Oral presentation preferred
• Paper poster presentation
• E-poster only
• Video presentation
• Oral presentation in the ENYGO Young investigator session (only for authors up to 40 years)
• Place holder for LBA
• Poster for Patient advocacy seminar

The Programme committee reserves the right to decide on the final allocation and presentation method.

• Disclosure of potential conflict of interest (e.g., grant support, consultancy, membership on advisory councils, speaker’s bureau) by all authors and source of funding are mandatory. The submitting author is responsible for collecting a Conflict of interest form for all co-authors. All disclosures should be listed within the last 3 years. A COI template is available here
• Abstracts submitted via commercial entities will be considered. However, these abstracts should report results from collaborative research conducted by independent (non-commercial) investigators. Investigators, as contributing authors who are employees of commercial entities will only be accepted if independent (academic, clinical and/or scientific) investigators are included as authors. The presenting author should not be an employee of the company.
• Systematic review/meta-analysis abstracts are acceptable.
• Video presentation (abstract): Please note the abstract shall be accompanied with the video file. The file should be in .mp4 format with max. size of 500MB and maximum 5 minutes long.
• Trials in progress (TiP) can be accepted as posters/e-posters but will not be accepted as oral presentations. These should not previously have been presented as TiP at an ESGO congress. TiP abstracts should be listed as a special category/topic. It is expected that abstracts submitted as TiP are ongoing trials that have not reached any protocol-specified endpoints for analysis.
• Encore abstracts (from key data presented at 2025 international meeting as an oral presentation) can be accepted only if they have not been published; with modification and new data, if possible.  In case of a conflict of interest, please do not hesitate to contact us for clarification.
• If several abstracts are based on similar analyses of the same database and more than one of them is selected for oral presentation, the authors might be asked to combine some/all data into one presentation.
• Case reports for single cases will not be accepted unless they contain substantial translational work.
• Late Breaking Abstracts (LBA) are reserved for newly emerging data that is not available at the time of abstract submission. These could be for initial presentation of results, or significant secondary endpoint analyses. A placeholder LBA must be submitted containing the title, background, methods and type of results that will be presented. LBA will not be accepted at a later date unless a shell abstract has been submitted.
• To keep transparency, please DO NOT refer to institution or hospital where the research took place in the body of the text.